ArticleEJHaem2025
The prognostic value of POD24 in relapsed/refractory follicular lymphoma-A SCHOLAR-5 analysis.
Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03105336 (A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Treatment and survival outcomes for patients with follicular lymphoma and POD24: a systematic review and meta-analysis.Blood advances · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Introduction: Follicular lymphoma (FL) has a heterogeneous prognosis. Progression within 24 months of starting front-line therapy (POD24) is prognostic of overall survival (OS). Despite its prognostic value in early lines, the role of POD24 in relapsed/refractory (R/R) patients initiating later lines of therapy (LoTs) is unknown. Methods: We analyzed the SCHOLAR-5 real-world cohort to investigate whether POD24 is prognostic in patients with R/R FL initiating ≥3rd LoT. Results: Among the 128 SCHOLAR-5 patients, 34 patients experienced POD24. POD24 patients received their ≥3 LoT after a shorter time compared with non-POD24 patients (median 42.0 months [range: 8.8‒17.8] vs. 109.9 months [range: 29.6‒310.2]). Using a time-dependent multivariate Cox model, POD24 was predictive of shorter OS from initiation of ≥3rd LoT with a hazard ratio (HR) of 2.44 (95% confidence interval [CI]: 1.20‒4.96). For progression-free survival, using a multivariate repeated-measures Cox model, the effect was similar but not statistically significant (HR: 1.45; 95% CI: 0.94‒2.11). Conclusion: This study demonstrates that among patients with R/R FL initiating a ≥3rd LoT, POD24 patients reach these LoTs sooner after diagnosis and POD24 remains prognostic of subsequent OS. This suggests that POD24 status can inform clinical decision making in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.